TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Noushin Farnoud(Memorial Sloan Kettering Cancer Center), David A. Sallman(Moffitt Cancer Center), Jeffrey E. Lancet(Cornell University), Sean M. Devlin(Memorial Sloan Kettering Cancer Center), Kendra Sweet(Moffitt Cancer Center), Christopher Famulare(Memorial Sloan Kettering Cancer Center), Pinkal Desai(NewYork–Presbyterian Hospital), Chetasi Talati(Moffitt Cancer Center), Gail J. Roboz(Cornell University)
Cited by 45
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k